Interview with Richard Hayes by Casey Walker
By Casey Walker,
Wild Duck Review
| 05. 31. 1999
Human Genetic Engineering
Richard Hayes Biography: is a doctoral candidate in Energy and Resources at U.C. Berkeley. His work focuses on long-term scenarios of economic well-being, ecological integrity, social equity and technological change. Rich is director of Genetic Crossroads, an activist organization primarily critiquing human germline engineering and cloning technologies; and is a member of the human genetics committee of the Council for Responsible Genetics. Rich has long been active as an organizer in progressive social and political movements. He served most recently as chair of the Sierra Club's global warming campaign committee, and before that as assistant political director and director of volunteer development on the national Sierra Club staff. Contact information:
rhayes@socrates.berkeley.edu
Casey Walker: Will you describe how you came to realize the significance of developments in human genetic manipulation and why you consider public involvement a matter of urgency?
Rich Hayes: As part of my dissertation studies at Berkeley I wanted to learn about the new human genetic technologies and their social implications. I did course work in genetics and began attending conferences. I was stunned by what I...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...